Multiple myeloma: detecting the eff ects of new treatments

Patients with malignant pleural mesothelioma who wish to be treated should be informed that strong medical evidence establishes the standard of care for malignant pleural mesothelioma as cisplatin and pemetrexed. Although cisplatin plus gemcitabine might be equally eff ective, there have as yet been no randomised comparisons of the two doublet

[1]  Michael Wang,et al.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. , 2007, The New England journal of medicine.

[2]  Alessandro Corso,et al.  Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. , 2007, The New England journal of medicine.

[3]  B. Pégourié,et al.  Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial , 2007, The Lancet.

[4]  P. Sonneveld,et al.  Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  B. Pégourié,et al.  Comparison of melphalan-prednisone-thalidomide (MP-T) to melphalan-prednisone (MP) in patients 75 years of age or older with untreated multiple myeloma (MM). Preliminary results of the randomized, double-blind, placebo controlled IFM 01–01 trial , 2007 .

[6]  R. Fonseca,et al.  Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology Group , 2007 .

[7]  P. Dickman,et al.  Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Vincenzo Callea,et al.  Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial , 2006, The Lancet.

[9]  Rafael Fonseca,et al.  Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Hartmut Goldschmidt,et al.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. , 2005, The New England journal of medicine.

[11]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[12]  B. Djulbegovic,et al.  Management of multiple myeloma: a systematic review and critical appraisal of published studies. , 2003, The Lancet. Oncology.

[13]  Beverly S Mitchell,et al.  Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  I. Hozo,et al.  Evaluation and appraisal of randomized controlled trials in myeloma. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .